PT-141 (Bremelanotide) Medicaid Coverage by State Tier: What You'll Actually Pay in 2026

Why Medicaid Coverage for Bremelanotide Is So Limited

Medicaid programs cover drugs listed on each state's preferred drug list (PDL). Vyleesi's placement is poor across nearly all states, and understanding why helps patients build a realistic access strategy.

The Federal Rebate Framework

Federal law under the Medicaid Drug Rebate Program (MDRP) requires manufacturers to pay rebates to states for covered outpatient drugs. Palatin Technologies entered the MDRP after FDA approval, meaning Vyleesi is technically eligible for Medicaid reimbursement. However, eligibility for the rebate program does not obligate any state to place the drug on its PDL. [1]

States retain broad discretion to restrict or exclude drugs that a Drug Utilization Review (DUR) board classifies as lifestyle medications or low-priority. HSDD is a recognized psychiatric and endocrine diagnosis in DSM-5 and ICD-10 (code F52.0), but many state DUR boards have historically treated sexual dysfunction medications as elective. [2]

How State PDL Tiers Work

Most state PDLs use a three-tier or four-tier architecture:

• Tier 1 (preferred generics): lowest copay, minimal barriers
• Tier 2 (preferred brands): moderate copay, sometimes step therapy required
• Tier 3 (non-preferred brands): higher copay plus prior authorization (PA)
• Non-formulary / excluded: PA required and almost never approved, or flat exclusion with no PA pathway

Vyleesi sits in Tier 3 or is excluded entirely in the states that have reviewed it. No state as of the 2026 PDL review cycle places it at Tier 1 or Tier 2. [3]

State-by-State Medicaid Coverage Tiers for Bremelanotide (2026)

Coverage status shifts as states update their PDLs annually, usually in January and July. The table below reflects the most recent published PDL decisions available at the time of this article's review. Patients should verify current status directly with their state Medicaid agency or a HealthRX care coordinator.

Tier A: Prior Authorization Pathway Exists (PA Rarely Approved)

These states list Vyleesi as non-preferred but maintain a written PA pathway. Approvals require documentation of an HSDD diagnosis by a licensed provider, failure of at least one non-pharmacological intervention, and evidence that the condition causes meaningful distress, consistent with the DSM-5 diagnostic criteria for HSDD. [4]

| State | PDL Tier | PA Criteria Summary | |---|---|---| | California | Non-preferred | HSDD diagnosis, clinician attestation, distress criterion | | New York | Non-preferred | HSDD diagnosis, psychiatric or gynecologic specialist note | | Illinois | Non-preferred | HSDD diagnosis, 90-day documented distress | | Washington | Non-preferred | Specialist referral required | | Massachusetts | Non-preferred | HSDD diagnosis, prior counseling attempt |

Even in these states, PA approval rates for Vyleesi are low. In a 2022 analysis of commercial and Medicaid PA decisions for female sexual dysfunction drugs, approval rates for non-preferred branded agents in Medicaid averaged 18%, compared with 54% in commercial plans. [5]

Tier B: Excluded with No Standard PA Pathway

The majority of states place Vyleesi in a blanket exclusion category. Patients in these states have no standard route to Medicaid reimbursement.

States in this category include (not exhaustive): Texas, Florida, Georgia, Ohio, Michigan, Pennsylvania, North Carolina, Arizona, Tennessee, Missouri, Indiana, Wisconsin, Colorado, Virginia, Minnesota, and approximately 25 additional states with PDLs last updated between July 2025 and January 2026.

Patients in Tier B states may still request an exception through their state's grievance and appeals process, but these decisions are typically upheld on appeal when the drug is categorically excluded. [6]

Tier C: Managed Care Plan Discretion

Several states operate Medicaid primarily through capitated managed care organizations (MCOs). In these states, the state agency sets a base PDL but MCOs may add supplemental coverage:

| State | MCO Flexibility | Notes | |---|---|---| | Oregon | Limited MCO discretion | OHA base PDL excludes Vyleesi; individual MCO plans may differ | | New Mexico | MCO discretion | Molina, Presbyterian Health Plan policies vary | | Louisiana | MCO discretion | Aetna Better Health LA has reviewed HSDD coverage separately |

Patients in MCO-dominant states should request the specific formulary document from their MCO, not just the state agency's base PDL. [7]

The Biggest Barrier: Prior Authorization Criteria Are Strict

Even where a PA pathway exists, the criteria mirror the clinical trial enrollment standards from the key Phase 3 trials. The RECONNECT trials (two identically designed Phase 3 studies, combined N=1,267 premenopausal women) required a formal HSDD diagnosis, baseline distress scores above a validated threshold on the Female Sexual Distress Scale-Revised (FSDS-R), and exclusion of relationship or psychosocial causes. [8]

Medicaid PA criteria in states like California and New York explicitly reference these diagnostic standards. A prescribing clinician must typically provide:

1. A confirmed F52.0 ICD-10 diagnosis with documented distress
2. Onset not attributable exclusively to another medical condition or medication
3. Documentation that a non-pharmacological approach (counseling, partner therapy) was attempted or is contraindicated
4. A note that the patient is premenopausal, consistent with the FDA label [9]

If the PA is denied, a prescribing physician has 30 to 60 days (state-dependent) to file an appeal or request a peer-to-peer review with the Medicaid medical director. Peer-to-peer reviews succeed more often when the prescriber is a board-certified gynecologist, reproductive endocrinologist, or sexual medicine specialist.

How to Get Bremelanotide Cheaper: Savings Programs and Alternatives

Because Medicaid coverage is limited, most patients access Vyleesi through three other routes.

Vyleesi Manufacturer Patient Assistance Program

Palatin Technologies and its commercialization partners operate a patient assistance program (PAP) for commercially uninsured or underinsured patients. As of 2026, eligibility typically requires household income at or below 400% of the federal poverty level (FPL), a valid prescription, and residency in the United States. Applications are processed through the prescribing provider's office.

Patients who qualify may receive Vyleesi at no cost or reduced cost for a defined period, usually 12 months with annual renewal. Contact information and current income thresholds are maintained on the FDA-approved prescribing information page for Vyleesi. [10]

Copay Assistance Cards (Commercial Insurance Only)

Vyleesi copay assistance cards reduce out-of-pocket costs for commercially insured patients. These cards do not apply to federal or state government insurance programs, including Medicaid, Medicare, CHIP, or TRICARE. Patients with Medicaid coverage cannot legally use manufacturer copay cards. This restriction derives from the federal anti-kickback statute as it applies to federal program beneficiaries. [11]

Compounded PT-141 from 503A Pharmacies

PT-141 in its peptide form (bremelanotide acetate) is available from compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded PT-141 is not FDA-approved, is not bioequivalent by regulatory definition to Vyleesi, and is not eligible for Medicaid reimbursement. However, cash-pay pricing at 503A compounding pharmacies typically ranges from $80 to $200 per vial (10 mg), substantially below the AWP of brand Vyleesi.

The FDA has not placed bremelanotide on its list of bulk drug substances that may be compounded under 503A, which means compounding pharmacies operate in a legal gray area. Patients considering this route should discuss it with their HealthRX provider. [12]

Dosing in the compounded form is typically 1.75 mg subcutaneously 45 minutes before sexual activity, matching the labeled dose of Vyleesi. [13]

GoodRx and Cash-Pay Discount Programs

GoodRx and similar programs negotiate discounts with retail pharmacies. Cash-pay prices for Vyleesi with a GoodRx coupon have ranged from $870 to $990 for a 4-dose kit at major chains, representing modest savings off AWP. These discounts are not Medicaid-equivalent and do not apply if the patient submits the claim to Medicaid.

HSA and FSA Eligibility for Bremelanotide

HSA (Health Savings Account) and FSA (Flexible Spending Account) funds can be used for prescription medications that treat a diagnosed medical condition. Bremelanotide prescribed for HSDD (ICD-10 F52.0) qualifies as a legitimate medical expense under IRS Publication 502. [14]

The requirement is a valid prescription from a licensed provider. Over-the-counter purchase is not available, so the prescription requirement is always met. Patients using compounded PT-141 from a 503A pharmacy with a prescription may also use HSA/FSA funds, though they should retain documentation of the diagnosis and prescription in case of an IRS audit.

Patients with an HSA-eligible high-deductible health plan (HDHP) can contribute up to $4,300 (individual) or $8,550 (family) to their HSA in 2026, per IRS limits. FSA contribution limits for 2026 are $3,300 per employee. Using these pre-tax dollars to cover Vyleesi's cash cost effectively reduces out-of-pocket expense by the individual's marginal tax rate, typically 22% to 32% for working adults. [15]

Clinical Context: Why HSDD Matters and What the Trials Showed

Understanding the clinical evidence behind bremelanotide helps patients and prescribers make the case for coverage in the PA process.

RECONNECT Phase 3 Trial Results

The two key RECONNECT trials enrolled 1,267 premenopausal women with HSDD diagnosed by DSM-5 criteria. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed before sexual activity over 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Function Index (FSFI) desire domain score and the FSDS-R item 13 distress score. [8]

Bremelanotide produced a statistically significant improvement in desire (least-squares mean change: +0.5 FSFI points vs. +0.2 placebo; P<0.001) and a significant reduction in distress (FSDS-R item 13: -0.3 vs. -0.2; P<0.001). Responder rates (patients reporting meaningful benefit on a Patient Global Impression of Improvement scale) were 24.5% for bremelanotide vs. 17.0% for placebo. [8]

The most common adverse effects were nausea (40.0% vs. 1.3% placebo), flushing (20.3%), and headache (11.0%). Transient increases in blood pressure (mean +6 mmHg systolic, +3 mmHg diastolic) occurred within 12 hours of dosing and resolved without intervention in most participants. [9]

Where Bremelanotide Fits in HSDD Management

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges both flibanserin (Addyi, a daily oral 5-HT1A agonist / 5-HT2A antagonist) and bremelanotide as FDA-approved pharmacological options for HSDD in premenopausal women. The guideline notes that choice between agents depends on patient preference for as-needed vs. Daily dosing, tolerability, and comorbidities. [16]

The HealthRX clinical team uses a three-step access framework for HSDD patients pursuing bremelanotide:

Step 1. Confirm diagnosis and document distress. Use the FSDS-R (validated, freely available) at baseline. A score above 11 on the full scale correlates with clinically meaningful distress and satisfies PA documentation requirements in most states that have a pathway.

Step 2. Determine insurance tier. For Medicaid patients, identify their state tier (A, B, or C above) and their MCO (if applicable). For Tier B states, proceed directly to PAP or compounding discussion. For Tier A states, file a PA with complete documentation before dispensing.

Step 3. Select the lowest-cost covered or cash-pay route. If PA is denied, compare Vyleesi AWP with HSA/FSA offset vs. Compounded PT-141 cash price. For most Tier B Medicaid patients, compounded PT-141 at $80 to $200 per vial is the most accessible route pending PAP approval.

What Medicaid Patients Should Ask Their Provider

Patients navigating Medicaid coverage for bremelanotide should bring specific questions to their appointment:

• "Can you document my FSDS-R score in the chart to support a prior authorization?"
• "Which Medicaid MCO am I enrolled in, and does that MCO's formulary differ from the state base PDL?"
• "Am I eligible for the Vyleesi PAP, and can your office submit the application?"
• "Is compounded PT-141 from a 503A pharmacy a reasonable option for me given my cardiovascular history?" (Bremelanotide is contraindicated in patients with known cardiovascular disease due to transient BP elevation. [9])
• "Can I use my FSA card at the pharmacy to cover the cash-pay cost?"

Practical Cost Comparison for Medicaid-Ineligible Patients

| Access Route | Estimated Monthly Cost | Key Conditions | |---|---|---| | Vyleesi AWP (no discount) | $1,040 per kit (4 doses) | Commercially insured or self-pay | | Vyleesi + GoodRx | $870 to $990 per kit | No Medicaid use | | Vyleesi PAP | $0 for eligible patients | Income <400% FPL, US resident | | Compounded PT-141 (503A) | $80 to $200 per vial (10 mg) | Cash-pay, not FDA-approved | | HSA/FSA offset (Vyleesi) | Effective $600 to $750 per kit | 22% to 32% tax bracket, with valid Rx |